COMPASS Pathways (NASDAQ:CMPS) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS

COMPASS Pathways (NASDAQ:CMPS) issued its quarterly earnings results on Thursday. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.03), Zacks reports. During the same quarter in the previous year, the business earned ($0.62) earnings per share.

COMPASS Pathways Stock Performance

Shares of NASDAQ CMPS traded up $0.16 during trading hours on Friday, reaching $7.04. 598,895 shares of the stock were exchanged, compared to its average volume of 423,448. The firm has a market capitalization of $481.40 million, a price-to-earnings ratio of -2.97 and a beta of 2.27. The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.23 and a current ratio of 15.23. COMPASS Pathways has a 52 week low of $5.01 and a 52 week high of $12.75. The stock’s fifty day simple moving average is $6.89 and its 200 day simple moving average is $8.58.

Analysts Set New Price Targets

Several brokerages recently commented on CMPS. HC Wainwright reissued a “buy” rating and set a $120.00 price target on shares of COMPASS Pathways in a research report on Wednesday. Canaccord Genuity Group reduced their price target on COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating for the company in a research report on Friday. Royal Bank of Canada assumed coverage on COMPASS Pathways in a research report on Tuesday, July 23rd. They set an “outperform” rating and a $23.00 price target for the company. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a research note on Friday, June 21st. Six analysts have rated the stock with a buy rating, According to MarketBeat, COMPASS Pathways has a consensus rating of “Buy” and a consensus target price of $43.00.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.